九典制藥(300705.SZ):第二個品種酮洛芬凝膠貼膏已於今年2月底獲批上市
格隆匯7月6日丨九典制藥(300705.SZ)近期在接待機構調研時表示,公司最早是在2003年的時候接受了一款中藥凝膠膏(當時還叫巴布膏)的委託研發,從而開始進入這個領域。公司在研發的過程中發現凝膠貼膏劑與傳統膏藥相比有療效顯著、安全性高、與皮膚相容性好等優點,克服了傳統貼膏對皮膚刺激性大、透氣性差、揭帖不方便等諸多缺點,能夠極大的造福患者,因而具有廣闊的市場空間;而且做起來技術難度比較高,公司經過了十幾年的摸索,去日本、韓國考察、學習,最終自己研究突破才掌握了凝膠貼膏劑研製技術。這是一個需要長期經驗和技術積累的過程,公司第一個品種洛索洛芬鈉凝膠貼膏2017年獲批上市,第二個品種酮洛芬凝膠貼膏已於今年2月底獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.